These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
494 related articles for article (PubMed ID: 12149307)
1. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG; J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307 [TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236 [TBL] [Abstract][Full Text] [Related]
3. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. Winer EP; Hudis C; Burstein HJ; Chlebowski RT; Ingle JN; Edge SB; Mamounas EP; Gralow J; Goldstein LJ; Pritchard KI; Braun S; Cobleigh MA; Langer AS; Perotti J; Powles TJ; Whelan TJ; Browman GP J Clin Oncol; 2002 Aug; 20(15):3317-27. PubMed ID: 12149306 [TBL] [Abstract][Full Text] [Related]
4. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Visvanathan K; Chlebowski RT; Hurley P; Col NF; Ropka M; Collyar D; Morrow M; Runowicz C; Pritchard KI; Hagerty K; Arun B; Garber J; Vogel VG; Wade JL; Brown P; Cuzick J; Kramer BS; Lippman SM; J Clin Oncol; 2009 Jul; 27(19):3235-58. PubMed ID: 19470930 [TBL] [Abstract][Full Text] [Related]
5. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention. Vogel VG Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712 [TBL] [Abstract][Full Text] [Related]
6. Current concepts in breast cancer chemoprevention. Chlebowski RT Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912 [TBL] [Abstract][Full Text] [Related]
7. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144 [TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Levine M; Moutquin JM; Walton R; Feightner J; CMAJ; 2001 Jun; 164(12):1681-90. PubMed ID: 11450210 [TBL] [Abstract][Full Text] [Related]
9. Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting? Gogas H; Markopoulos C; Blamey R Ann Oncol; 2005 Dec; 16(12):1861-6. PubMed ID: 15980159 [TBL] [Abstract][Full Text] [Related]
10. Breast cancer prevention trials. Rhodes DJ; Hartmann LC; Perez EA Curr Oncol Rep; 2000 Nov; 2(6):558-65. PubMed ID: 11122893 [TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250 [TBL] [Abstract][Full Text] [Related]
12. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036 [TBL] [Abstract][Full Text] [Related]
13. Upstaging tamoxifen? New classes of drugs emerging for breast cancer. Twombly R J Natl Cancer Inst; 2002 Apr; 94(7):474-5. PubMed ID: 11929942 [No Abstract] [Full Text] [Related]
14. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143 [TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of breast cancer. Thomsen A; Kolesar JM Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189 [TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Temin S Gynecol Oncol; 2009 Oct; 115(1):132-134. PubMed ID: 19716939 [No Abstract] [Full Text] [Related]
17. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer. Anderson C; Nichols HB; House M; Sandler DP Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499 [TBL] [Abstract][Full Text] [Related]
18. Exemestane for primary prevention of breast cancer in postmenopausal women. Zhang Y; Simondsen K; Kolesar JM Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103 [TBL] [Abstract][Full Text] [Related]
19. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Nelson HD; Smith ME; Griffin JC; Fu R Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749 [TBL] [Abstract][Full Text] [Related]
20. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Vogel VG Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]